# A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

> **NCT04762277** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 52 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Spesolimab - solution for infusion
- **DRUG:** Placebo matching spesolimab - solution for infusion
- **DRUG:** Spesolimab- solution for injection
- **DRUG:** Placebo matching to spesolimab- solution for injection

## Key facts

- **NCT ID:** NCT04762277
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-06
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-04-21
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762277, "A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04762277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*